MAS825

Phase 2

Novartis AG (NVS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

NVSPhase 2$271.5B

MAS825 Phase 2 Est. Readout

MAS825• COVID-19 Pneumonia, Impaired Respiratory Function30

Q2 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in COVID-19 Pneumonia, Impaired Respiratory Function

View Full Landscape

Drug Information

Target Indication

COVID-19 Pneumonia, Impaired Respiratory Function

Clinical Trial

NCT04382651

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

lisinoprilPhase 3

Hypertension

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts